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The aim of this study was to identify and characterize mech-
anisms of resistance to antifolate drugs in African trypano-
somes. Genome-wide RNAi library screens were undertaken in
bloodstream form Trypanosoma brucei exposed to the antifo-
lates methotrexate and raltitrexed. In conjunction with drug
susceptibility and folate transport studies, RNAi knockdown
was used to validate the functions of the putative folate trans-
porters. The transport kinetics of folate and methotrexate were
further characterized in whole cells. RNA interference target
sequencing experiments identified a tandem array of genes
encoding a folate transporter family, TbFT1–3, as major con-
tributors to antifolate drug uptake. RNAi knockdown of
TbFT1–3 substantially reduced folate transport into trypano-
somes and reduced the parasite’s susceptibly to the classical
antifolates methotrexate and raltitrexed. In contrast, knock-
down of TbFT1–3 increased susceptibly to the non-classical
antifolates pyrimethamine and nolatrexed. Both folate and
methotrexate transport were inhibited by classical antifolates
butnot bynon-classical antifolates or biopterin.Thus,TbFT1–3
mediates the uptake of folate and classical antifolates in
trypanosomes, andTbFT1–3 loss-of-function is amechanismof
antifolate drug resistance.
The neglected tropical disease human African trypanosomi-
asis (HAT),3 also known as African sleeping sickness, threatens
70 million people in 24 sub-Saharan African countries (1).
HAT is primarily transmitted by the tsetse fly and is caused by
two subspecies of the unicellular protozoan parasite Trypano-
soma brucei: T. brucei gambiense, an anthroponotic disease
mainly affecting humans with a minor animal reservoir; and
T. brucei rhodesiense, a zoonotic disease affecting mainly ani-
mals with humans inadvertently infected. Both forms of HAT
clinically evolve in two stages, an early hemolymphatic stage
and a second meningoencephalitic stage, with a fatality rate
close to 100% if left untreated (2, 3). T. brucei rhodesienseHAT
is an acute disease that rapidly progresses to death within 6
months (4), whereas T. brucei gambiense HAT has a more
chronic course with an average duration of 3 years (5).
Although new cases of HAT have fallen to below 7,000 in 2011,
the disease carries amajor risk of resurgencewith epidemiolog-
ical population shifts, climate change, and civil unrest (1, 6).
The disease is a key factor in maintaining the poverty cycle in
neglected communities, and it is also a stigmatizing disease
causing neuropsychological impairment and abandonment for
its suffers (7, 8). In 2012, the World Health Organization tar-
geted elimination ofT. brucei gambienseHAT (which accounts
for 98% of HAT cases) by 2020 (9).
Current drugs used for the treatment of HAT are far from
ideal with many shortcomings, such as high cost, severe toxic-
ity, and the emergence of resistance (10). Nifurtimox/eflorni-
thine combination therapy is the newest treatment to be used
clinically, but the ease of resistance developing in the field is a
concern (11, 12). Development of new drugs could enable the
elimination of T. brucei gambiense HAT. Essential metabolic
pathways of the parasite are being exploited to identify poten-
tial drug targets, and folate metabolism is one such pathway.
T. brucei, like all trypanosomatids, is auxotrophic for folates
(13, 14), and some of the enzymes responsible for intracellular
folate metabolism have been investigated as potential drug tar-
gets. For example, the bifunctional enzyme dihydrofolate
reductase-thymidylate synthase (DHFR-TS) and pteridine
reductase 1 (PTR1) have been found to be essential for parasite
survival, and potent inhibitors of TbDHFR-TS and TbPTR1
have good antitrypanosomal activity (13–17).
In addition, the classical antifolatesmethotrexate (MTX) and
raltitrexed (RTX) were found to have nanomolar potency
against T. brucei when tested in culture media with a folate
concentration similar to that in human serum (13, 14). Utiliza-
tion of folate-depleted medium for screening antifolates is nec-
essary as the standard media for T. brucei cell culture, HMI9-T
medium, contains folate at 440 times (range 140–2,000) the
plasma concentration in humans (18). The impact of this high
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non-physiological folate concentration could reduce the anti-
trypanosomal potency of antifolate inhibitors through compe-
tition for drug uptake, interference with cellular retention by
competition for polyglutamylation by folylpolyglutamate syn-
thase (FPGS), or through competition for the active site of tar-
get enzymes (e.g. DHFR-TS).
We used a genome-wide RNA interference screening
approach to identify potential antifolate resistance mecha-
nisms, an approach that has been used successfully for other
antitrypanosomal compounds (19, 20). Here, MTX (a DHFR
and PTR1 inhibitor) and RTX (a TS inhibitor) were chosen as
model antifolates as these drugs display potent activity against
T. brucei (13, 14). We report the role of the folate transporter
gene family (FT1–3), identified in our RIT-seq screen, in medi-
ating folate uptake. Subsequently, we characterize the kinetics
of folate and MTX transport and demonstrate substrate com-
petition between folate andMTX.Our experiments also distin-
guish between classical and non-classical antifolate entry into
trypanosomes and suggest a role of p-aminobenzoylglutamate
(pABA-Glu) in facilitating the uptake of non-classical antifo-
lates and therefore their efficacy.
Results
RIT-seq Screens Identify Candidate Antifolate Resistance
Mechanisms—A trypanosome RNAi library was exposed to a
typically lethal dose of either the DHFR inhibitor, MTX, or the
TS inhibitor, RTX (Fig. 1, A and C). Under tetracycline induc-
tion, each T. brucei cell produces dsRNA from the integrated
RNAi target fragment, and knockdownhas the potential to con-
fer a selective advantage under drug pressure. RIT-seq was sub-
sequently used to generate a readout from the population that
tolerated this regime. PCR products representing RNAi target
fragments, derived from the RNAi screen, were separated on
an agarose gel, and low-throughput RIT-seq of multiple frag-
ments implicated the putative folate transporter genes
(FT1–3: Tb927.8.3620, Tb927.8.3630, and Tb927.8.3650) in
both the MTX and RTX screens. These folate transporters
share 96% nucleotide identity and are arranged in tandem,
interrupted by an unrelated gene (Tb927.8.3640) on chro-
mosome 8.
High-throughput RIT-seq confirmed and extended these
hits as follows: 2.4 million paired-end reads, of which 70%
mapped to the reference genome for MTX, and 2.6 million
paired-end reads, of which 71% mapped to the reference
genome for RTX (Table 1). FT1–3 and a truncated orphan
folate transporter gene (Tb11.v5.0766) are the strongest “hits”
in both the MTX and RTX screens, accounting for90% of all
mapped reads (Fig. 1, B and D). We also note that 95% of the
“MTX” and “RTX” reads mapped against a reference genome
that included the T. brucei 427 telomeric variant surface glyco-
protein expression site regions; in addition to encoding variant
surface glycoproteins, these regions containESAG10 genes that
also encode putative folate transporters related to FT1–3. A
gene encoding a mitochondrial carrier protein (MCP2,
Tb927.11.14360) was also common to both screens (Fig. 1, B
and D, and Table 1), whereas C-1-tetrahydrofolate synthase,
also referred to as the bifunctional tetrahydrofolate dehydroge-
nase/cyclohydrolase (DHCH, Tb927.7.1600), was specific to the
RTX screen (Fig. 1D and Table 1). A notable “hit” only sup-
ported by a single RIT-seq fragment in the RTX screen was
folylpolyglutamate synthase (FPGS, Tb927.10.7520, Table 1)
implicated in folate retention by polyglutamylation. The puta-
tive pteridine transporter genes on chromosomes 1 and 10
failed to register as hits in either screen. Thus, although pteri-
dine transporters aremembers of the folate biopterin transport
(FBT) family, in T. brucei they do not appear to be involved in
the transport of antifolates.
Folate andMTXTransport Kinetics—As the RIT-seq screens
implicated folate transporters in antifolate drug resistance,
transport studies of folate andMTXwere undertaken to deter-
mine basic kinetic parameters. Folate uptake was found to be
linear over 150 s and directly proportional to concentration up
to 10 M at 23 °C (Fig. 2A). A plot of the y axis intercepts (time
0) versus folate concentration is linear (Fig. 2B), suggesting non-
specific binding of folate to the trypanosome outer surface. The
rate of uptake of folate was temperature-dependent (Fig. 2C)
with a 12-fold higher rate at 23 °C (0.24  0.03 pmol s1 (108
cells)1) compared with 4 °C (0.02  0.01 pmol s1 (108
cells)1). Uptake rates for folate obeyed simpleMichaelis-Men-
ten kinetics (Fig. 2D) yielding aKm of 2.04 0.53Mand aVmax
FIGURE1.RIT-seq screens identify candidate antifolate resistancemechanisms. Thegenome-wide RIT-seqmaps indicate hits from theMTX (A) andRTX (B)
RNAi screens.Multiple RIT-seq fragments represent primary hits, indicated in green. Other loci withmapped reads are indicated in gray. The profiles forMTX (C)
and RTX (D) indicate hits in green; other protein coding sequences are indicated as black bars. Red peaks, forward reads with RNAi-construct barcodes; blue
peaks, reverse reads with RNAi-construct barcodes; gray peaks, all other reads.
Folate Transport in the African Trypanosome
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of 0.20  0.04 pmol s1 (108 cells)1. In the same way, MTX
uptake was found to be linear over 150 s up to 20M (Fig. 3A) at
23 °C with evidence of nonspecific binding (Fig. 3B) and tem-
perature dependence (Fig. 3C (0.40  0.06 and 0.03  0.01
pmol s1 (108 cells)1) at 23 and 4 °C, respectively). MTX
uptake also obeyed simpleMichaelis-Menten kinetics (Fig. 3D)
yielding aKm of 18.4 2.2M andVmax of 0.76 0.08 pmol s1
(108 cells)1.
FT1–3 Transport Folate and Classical Antifolates—To vali-
date the RIT-seq analysis, we performed knockdown of FT1–3
in independent RNAi strains. Tetracycline-induced knock-
down showed no significant change in growth over a 6-day
period when compared with wild-type or un-induced controls
(Fig. 4A). RNA analysis using qRT-PCR confirmed FT1–3
mRNA knockdown after 3 days of induction (p  0.02) and
after 6 days of induction (p 0.001) (Fig. 4B).
RNAi knockdown of FT1–3 greatly reduced Vmax of folate
uptake at 3 and 6 days after induction (Fig. 4C). After 3 days, the
Vmax of induced cells was 10- and 9-fold lower than wild-type
and un-induced cells, respectively. Similarly by day 6, the Vmax
of induced cells was 4-fold lower than wild-type and un-in-
duced cells. No changes in Km values were detected, with Km
values in the range 2.56–3.47Mobtained for all three cell lines
after 3 or 6 days of induction.
EC50 determinations showed a30-fold decrease in suscep-
tibility for MTX and RTX after 3 and 6 days of FT1–3 knock-
down, respectively (Table 2). In contrast, susceptibility to the
non-classical DHFR inhibitor pyrimethamine increased by
12-fold after 3 days and by 14-fold after 6 days of knockdown.
Likewise, susceptibility to the non-classical TS inhibitor
nolatrexed also increased by 2-fold after 3 and 6 days of
knockdown. No marked change of EC50 for the control
TABLE 1
Hits identified through RIT-seq screening
Hit list showing RPKM for barcoded reads (103); only genes with RPKM 1000 for barcoded reads and RPKM 200 for all mapped reads are included. MTX,
methotrexate screen; RTX, raltitrexed screen.
Gene ID Gene description MTX reads RTX reads
Tb927.8.3620 Folate transporter, putative 387.4a 425.6a
Tb927.8.3650 Folate transporter, putative 190.1a 139.4a
Tb927.8.3630 Folate transporter, putative 107.0a 125.5a
Tb11.v5.0766 Folate transporter, putative (truncated) 85.4a 78.9a
Tb927.11.14360 Mitochondrial carrier protein (MCP2) 16.6a 4.0a
Tb927.7.1600 C-1-tetrahydrofolate synthase, cytoplasmic, putative 0 57.3a
Tb927.11.12460 Hypothetical protein, conserved 0 3.6
Tb927.8.1040 Protein phosphatase inhibitor, putative 2.1 0.5
Tb927.9.5960 Succinate dehydrogenase, putative 1.7 0
Tb927.10.7520 Folylpolyglutamate synthase, putative (FPGS) 0 1.2
Tb927.8.5840 Hypothetical protein, conserved 1.2 0
a Primary hit with1 fragment per gene; others, secondary hits with only one fragment per gene. GeneID and description information is from tritrypdb.org.
FIGURE 2. Folate transport kinetics. A, linearity of folate uptake at 23 °C. Time points at 30 s for 10 and 8 M are not available due to loss of pellet during the
experiment. B, intercepts (from A, time 0) as a function of folate concentration. Linear regression analysis uses explicit weighting for the fit to take into account
the higher errors at the higher concentrations.C, effect of temperature on folate uptake. Trypanosomeswere incubatedwith 10M folate at 23 °C (open circles)
or 4 °C (closed circles) and samples processed at intervals. Data are themean and S.E. of triplicate samples.D, transport kinetics for folate. Rates were obtained
from the slopes of data in A and fitted to the Michaelis-Menten equation.
Folate Transport in the African Trypanosome
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arsenical drug, melarsoprol, was evident after 3 or 6 days of
knockdown.
Inhibition of Folate and MTX Transport by Alternative
Substrates—To further assess the interactions between
trypanosomes and antifolates, we determined whether “folate-
like molecules” had an effect on folate or MTX uptake. Folate
uptake was inhibited by MTX, RTX, pemetrexed, and 5-
methyl-THF (Fig. 5A). In contrast, uptake of folate was not
inhibited by compounds lacking a pABA-Glu-like moiety,
namely trimetrexate, nolatrexed, trimethoprim, pyrimetham-
ine, or biopterin (see Fig. 5C for chemical structures). Consist-
ent with this observation, pABA-Glu itself substantially
reduced folate uptake (21% residual uptake). MTX uptake was
inhibited by the same classical antifolates or folic acid but not
by the non-classical antifolates (Fig. 5B). As for folate, pABA-
Glu also substantially reduced MTX uptake (11% residual
uptake). Biopterin did not inhibit folate or MTX uptake, in
agreementwith the failure of theRIT-seq screens to identify the
putative pteridine transporter genes on chromosomes 1 and 10.
Finally, we determined the IC50 values of folate analogues
against uptake of either radiolabeled folate or MTX. MTX
inhibited folate uptake with an IC50 of 3.4  0.4 M, and folic
acid inhibited uptake of MTX with an IC50 of 1.9  0.4 M
(Table 3). The classical antifolates RTX and pemetrexed had
similar potencies to MTX in inhibiting folate uptake. pABA-
Gluwas aweaker inhibitor of both folate andMTXuptake (IC50
values of 30.8 3.7 and 33.5 4.6 M, respectively) (Table 3).
To determine whether MTX competes with folate for uptake,
transport rates were determined for varying concentrations of
FIGURE 3.Methotrexate transport kinetics. A, linearity ofMTX uptake at 23 °C. The time point at 30 s for 20M is not available due to loss of pellet during the
experiment. B, intercepts (from A, time 0) as a function of MTX concentration. Linear regression analysis uses explicit weighting for the fit to take into account
the higher errors at the higher concentrations. C, effect of temperature on MTX uptake. Trypanosomes were incubated with 20 M MTX at 23 °C (open circles)
or 4 °C (closed circles) and samples processed at intervals. Data are the mean and S.E. of triplicate samples. D, transport kinetics for MTX. Rates were obtained
from the slopes of data in A and fitted to the Michaelis-Menten equation.
FIGURE 4. FT1–3 knockdown and impact on folate transport. A, cumu-
lative growth of wild-type (WT) cells and FT RNAi strains with or without
tetracycline (tet) induction. Closed squares, WT; closed circles, RNAi knock-
down minus tetracycline induction; open circles, RNAi knockdown with
tetracycline induction. B, qRT-PCR shows down-regulation of FT RNA: tran-
script change of FT with or without tetracycline induction, normalized
against endogenous control gene TERT. C, folate transport kinetics mea-
sured at day 3 and day 6 in WT cells and FT RNAi strains with or without
tetracycline induction.
Folate Transport in the African Trypanosome
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folate in the presence of fixed concentrations ofMTX (Fig. 6A).
The resulting Lineweaver-Burk plot suggested either a compet-
itive or mixed inhibition pattern. An F-test in GraFit estab-
lished that these data fitted best to competitive inhibition,
yielding aKi value forMTXof 0.48 0.07M.A similar analysis
revealed that folate is a competitive inhibitor ofMTX transport
with a Ki value of 0.94  0.21 M (Fig. 6B). If two substrates
compete for the same target or enzyme, in this case the folate
transporter, Equations 6 or 7 (see derivation under “Experi-
mental Procedures”) can be used to calculate the IC50 for any
TABLE 2
Effect of RNAi knockdown of folate transporters FT1–3 on susceptibility to antifolates
EC50 values (nM) of drugs against uninduced and induced FT knockdown cells. Results are weighted means weighted error of three independent experiments.
Drug
3 days 6 days
Minus tetracycline Plus tetracycline -Fold shift Minus tetracycline Plus tetracycline -Fold shift
Methotrexate 14.5 0.4 444 16.9 30.6 8.73 0.39 321 12.8 36.8
Raltitrexed 11.2 0.3 368 13.7 32.9 5.83 0.20 227 9.68 38.9
Pyrimethamine 2,500 120 200 11.0 0.08 20,40 165 142 10.4 0.07
Nolatrexed 36,200 1,910 16,700 957 0.46 39,900 2,480 15,600 886 0.39
Melarsoprol 1.73 0.09 1.70 0.08 0.98 1.26 0.60 1.29 0.59 1.02
FIGURE 5.Effect of antifolates and folatemetabolites onuptakeof folate orMTX.Uptake of folate (A) andMTX (B) wasmeasured in the presence of 100M
of each inhibitor. Black bar, DMSO control; gray bars, non-folate-like structures; white bars, folate-like structures. The standard assay mixture is modified to
contain [S] Km and corrected for additional DMSO (0.4%). C, chemical structures of drugs and metabolites.
TABLE 3
Uptake of folate andMTX in the presence of varying concentrations of inhibitor
The standard assay mixture was modified to contain S	 Km and corrected for additional DMSO (0.4%). IC50 was calculated by fitting to a two-parameter IC50 equation.
ND not determined.
Substrate IC50 against folate IC50 against MTX Km Vmax Calculated IC50
M M M pmol s1 (108 cells)1 M
Methotrexate 3.4 0.4 16.5 0.68 2.2
Folic acid 1.9 0.4 2.07 0.19 2.9
5-Methyl-THF 6.3 1.0 8.0 0.8
pABA-Glu 30.8 3.7 33.5 4.6
Pemetrexed 3.2 0.3 ND
Raltitrexed 1.8 0.4 ND
Folate Transport in the African Trypanosome
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concentration of ligand. Applying experimental values to these
equations yielded an IC50 for MTX of 2.2 M against folate
uptake (Equation 6) and an IC50 value for folate of 2.9 M
against methotrexate uptake (Equation 7). These values are in
good agreement with the EC50 values determined experimen-
tally (Table 3), thus giving further evidence of a competitive
substrate model for folate and MTX transport by FT1–3.
Discussion
Our experiments have identified functional folate transport-
ers inT. brucei. The folate biopterin transporter (FBT) family is
a novel class of membrane proteins and superfamily of trans-
porters that were first characterized in Leishmania (21, 22) and
are found in other kinetoplastids (23) (including T. brucei),
malaria (24), Toxoplasma (25), plants (26) and cyanobacteria
(26). The T. brucei reference genome encodes eight FBT genes
as follows: in tritrypdb.org (version 9.0), four of are annotated as
putative folate transporters, with FT1–3 (Tb927.8.3620,
Tb927.8.3630, and Tb927.8.3650), clustered together on chro-
mosome 8 and a truncated orphan gene on chromosome 11
(Tb11.v5.0766); and four annotated as putative pteridine
transporters, with three (Tb927.1.2820, Tb927.1.2850, and
Tb927.1.2880) clustered together on chromosome 1 and an
orphan gene on chromosome 10 (Tb927.10.9080). The putative
folate transporters are predicted by the TMHMM server ver-
sion 2.0 to contain 12 transmembrane helices consistent with
other folate transporters. The orphan FT gene (Tb11.v5.0766)
shares 97–100% sequence identity to FT1–3 (position 736–
1899 ofORF), but this gene encodes a protein that lacks the first
245 amino acid residues that are predicted to encode the first
four transmembrane segments and therefore is likely to be non-
functional. There are also seven expression site-associated
genes (ESAG10) in the T. brucei S427 strain that share 84–91%
amino acid identity with FT1–3. ESAG10s are located in about
half of the specialized telomeric transcription units (Blood-
stream Expression Sites (BES)) devoted to expression of variant
surface glycoproteins (27). Only one BES is actively transcribed
at any time, and our lines express VSG221 from a BES that lacks
ESAG10 (27). VSG221 expression is checked periodically and is
consistently found to be the case for99% of these cells. Thus,
FT1–3 are likely the only expressed and functional folate trans-
porters in bloodstream-form T. brucei.
In contrast to the seven FBT homologues in T. brucei, Leish-
mania has 14 FBTs, and the function of 3 members, BT1, FT1,
and FT5 is known. FT5 is a high affinity/low capacity trans-
porter of folate/MTX (21), and FT1 is the main folate trans-
porter in Leishmania (high affinity/high capacity for folate/
MTX) (28). In contrast, BT1 is a biopterin transporter that
mediates uptake of biopterin and folate but not MTX (29).
From our experiments in T. brucei, folate and MTX share the
same transporter system, FT1–3, which is not shared by biop-
terin, a similar finding to that in Leishmania. It would be inter-
esting to establish whether the other four members of the
T. brucei FBT family do indeed mediate uptake of biopterin. In
Leishmania, the FBT family was annotated in tritrypdb.org as
pteridine transporters; however, there is a fourth member of
this gene family, AdoMetT1, that has recently been discovered
tomediate the specific transport of S-adenosylmethionine (30).
RNAi knockdown of FT1–3 dramatically reduced folate
transport, and competition assays with antifolates indicated
that folate and classical antifolates share a common transport
mechanism via folate transporters, which is not the case for
non-classical antifolates. Indeed, classical antifolates bear a
close structural resemblance to folate and use the same mech-
anism as folates for cell entry via specific transporters in human
cells; in contrast, non-classical antifolates are lipophilic, do not
contain a terminal glutamylmoiety, and enter cells by passive or
facilitated diffusion (31–33). In our experiments involving
knockdown of FT1–3, uptake of both folate and classical anti-
folates was reduced, leading to depletion in intracellular drug
levels and loss of potency against the intracellular drug target
DHFR-TS (13). However, in the case of non-classical antifo-
lates, uptake of the drug is not affected by knockdown, whereas
uptake of folate is reduced, leading to diminished intracellular
folate to compete for the drugs’ target (DHFR-TS) and there-
fore improved drug potency.
Our competition assay also provided further insight into the
structural recognition of folate for its uptake via transporters.
pABA-Glu inhibited folate and MTX transport, whereas biop-
terin had no effect on transport. This indicates that structures
that contain pABA-Glu (5-methyl-THF, folate) or a pABA-
Glu-like moiety (classical antifolates) compete for uptake into
cells (Fig. 5C). Indeed the - and -glutamate carboxyl groups
FIGURE6.Modeof inhibitionof folate transport byMTXandvice versa.A, KideterminationofMTXwith respect to folate. Folate concentrationswere varied
in thepresenceof fixed concentrations ofMTX.MTXwas addedat 0M (open circles), 0.5M (closed circles), and1M (open squares).B, Kideterminationof folate
with respect to MTX. Folate was added at 0M (open circles), 0.5M (closed circles), and 1M (open squares), and MTX was the variable substrate. The lines are
best fits to linear competitive inhibition (Equation 1).
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of the classical antifolates are negatively charged at physiologi-
cal pH and thus require carrier-mediated uptake for entry into
cells (34). The addition of a pABA-Glumoiety to a non-classical
antifolate, such as pyrimethamine, could lead to improved drug
uptake via transport and might also compete for folate uptake,
potentially leading to increased drug potency. Conversely, one
advantage of non-classical lipophilic antifolates over classical
antifolates is the reduced risk of transport-related resistance
occurring (35, 36). This observation has implications for future
chemotherapy. Drug resistance in T. brucei can arise due to
deletions disrupting genes encoding drug transporters as fol-
lows: AQP2 and AT1 in the case of melarsoprol resistance (37,
38) and AAT6 in the case of eflornithine resistance (12). A sim-
ilar mechanismmay lead to antifolate resistance, in which case
a strategy of rotating between classical and non-classical anti-
folates or using a combination of classical and non-classical
antifolates for chemotherapy may minimize resistance emerg-
ing. Alternative resistance mechanisms involving overexpres-
sion of target enzymes in Leishmania (39, 40) or mutation in
target enzymes in malaria parasites (41) have been described,
however.
The properties of folate transport in the T. brucei blood-
stream form are quite similar to that found in Leishmania,
where uptake is rapid and linear for 2–3 min in both parasites
(42) The rate of uptake is also concentration-dependent, high-
lighting a carrier-mediated mechanism of transport. Both
transport systems exhibit Michaelis-Menten kinetics, with Km
value for Leishmania parasites in the high nanomolar to low
micromolar range, depending upon the species (42). In con-
trast, mammalian cells show amuch lower affinity for uptake of
folic acid (100-fold less affinity that inT. brucei) and have a very
high affinity for 5-methyl-THF, the principal form of folate in
human serum (43). The Km or Ki values for 5-methyl-THF
transport in mammalian tumor cells (range 1–4 M) (44) is
comparablewith theKmof folate inT. brucei (2.1M). Likewise,
T. brucei was shown to have a lower affinity for MTX uptake
with aKm of 16M, as is the case formammalian cells (range 2.3
to 26 M) (44).
As well as shedding light on the role of FT1–3 in MTX and
RTX drug resistance, which led to the exploration of transport
kinetics of folate and antifolate drugs, our RIT-seq experiments
also identified other hits of interest. The mitochondrial carrier
protein 2 (MCP2) was a hit in both drug screensMitochondrial
carrier proteins are a group of structurally conserved proteins
that regulate the transport of a variety of metabolic intermedi-
ates across the mitochondrial membrane; 24 mitochondrial
carrier proteins have been identified in T. brucei (45). Phyloge-
netic reconstruction shows TbMCP2 on a branch with the
human folate transporter, SLC25A32, and TbMCP2 has been
confirmed as mitochondrial by Myc tagging (45). One-carbon
metabolism in mammalian cells is compartmentalized in the
cytosol,mitochondrion, and nucleus (46). However, the subcel-
lular localizations of key enzymes in folate-dependent pathways
have yet to be fully elucidated in African trypanosomes.
Methionyl-tRNAMet formyltransferase, required for initiation
of mitochondrial protein biosynthesis, has been localized
experimentally to this organelle (47). In addition, proteomic
analysis of enrichedmitochondrial preparations from T. brucei
identified all components of the glycine cleavage system as
mitochondrial (48). Other folate enzymes (DHFR-TS and
DHCH) were identified by enrichment, but a mitochondrial
location has not been confirmed. Underlining this uncertainty,
DHCH is localized exclusively in the cytosol in the related
trypanosomatid, Leishmania major (49). Nonetheless, the fact
that at least some folate-dependent metabolic enzymes have a
confirmed mitochondrial location indicates that folates must
be transported into this organelle.
Notably, DHCH and the “minor hit” FPGS were specific to
RTX in RIT-seq experiments. DHCH is a bifunctional enzyme
catalyzing formation of THF fromN5,N10-methylene-THF in a
two-step reaction (50). Decreased DHCH activity would result
in accumulation ofN5,N10-methylene-THF and increased con-
version of dUMP to dTMP by TS for DNA synthesis, thus pro-
viding an additional mechanism of resistance to RTX, a TS-
targeted antifolate. Moreover, RTX has a terminal glutamyl
moiety that is polyglutamylated in vivo by FPGS (51). RTX is
fully active after polyglutamylation (52) resulting in tighter
binding to its target TS and improved cellular retention. RTX
has shown to be more potent against whole parasites than
against recombinant TbDHFR or TbTS (13) suggesting that
polyglutamylation is likely to occur inside T. brucei. Thus, we
propose that this is the mechanism by which FPGS knockdown
reduces RTX potency.
An alternative approach to drug discovery is therapeutic
switching, i.e. the utilization of known approved drugs already
used in the treatment of many other human diseases. Indeed,
there aremany antifolate drugs that are clinically in use, mainly
developed as anticancer, antimalarial, and antibacterial drugs
that have also shown success in the treatment of toxoplasmosis
as well as promising potential against cryptosporidiosis (53).
Most are available as oral preparations and many have good
central nervous system penetration; these two pharmacological
properties concurwith the goal ofDrugs forNeglectedDiseases
initiative of delivering a new oral only treatment for stage 2
sleeping sickness to the clinic (54). The folate biosynthetic
pathway in T. brucei has yet to be fully exploited, and future
endeavors to understand the underlying mechanisms involved
in these pathways will play a central role when designing and
refining new and existing antifolates. Our studies have identi-
fied a key role of the folate transporter genes, FT1–3, in the
uptake of folate and folate analogues. This provides new insight
into potential resistance mechanisms and chemotherapy strat-
egies using antifolates.
Experimental Procedures
Chemicals—Folic acid, biopterin, and p-amino benzoyl-L-
glutamic acid were purchased from Schircks Laboratories.
[3H]Folic acid (64 Cimmol1) and [3H]MTX (38.2 Cimmol1)
were purchased from Hartmann Analytical. DHFR-TS inhibi-
tors were sourced as follows: MTX, trimethoprim and pyrim-
ethamine from Sigma; nolatrexed, pemetrexed, and RTX from
Sequoia Research Products; and trimetrexate from Tocris Bio-
science.Melarsoprol was obtained fromRhone-Poulenc. Other
chemicals and reagents used in this study were of the highest
grade and purity available.
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Trypanosomes and Culture Media—For routine culture,
T. brucei bloodstream-form “single marker” S427 (55) and 2T1
(56) strains were cultured at 37 °C in the presence of 5% CO2 in
HMI9-T medium. HMI9-T medium contains high concentra-
tions of thymidine (160 M) and folate (9 M), the latter
principally from Iscove’smodifiedDulbecco’smediumand 10%
Serum Plus components (14). A medium based on HMI9-T,
lacking Serum Plus, folate, and thymidine, and using 200 M
2-mercaptoethanol in place of 56 M 1-thioglycerol, was pre-
pared in-house and named T. brucei base media (TBM) (13).
Residual folate in TBM is provided by the 10% fetal calf serum
component. Wild-type S427 and 2T1 T. brucei cells grow nor-
mally in TBM, and the rate of growth is similar to HMI9-T
(7–8-h doubling time).
RNAi Screening and RIT-seq—An RNAi library screen was
performed inTBMand carried out as described previously (57).
Briefly, the RNAi library was induced on day 0 with tetracycline
(1 g ml1) and maintained under blasticidin (1 g ml1) and
phleomycin (1 g ml1) selection at a minimum of 2.5  107
cells in 150 ml of media. Following induction for 24 h, 15 nM
MTX or 10 nM RTX (3–4 EC50 for parasites cultured in
TBM for 48 h) was added. Cultures were split and supple-
mented with fresh drug as required. At day 4, concentrations of
MTX and RTX were increased to 30 nM. DNA was extracted
from drug-resistant cells on day 10. RNAi target fragments
were then amplified by PCR using the LIB2f and LIB2r primers.
For low throughput identification of fragments, PCR products
were separated on an agarose gel, and individual bands were
excised and sequenced using the Lib2f and Lib2r primers (57).
For high throughput identification of fragments, the PCR prod-
ucts were fragmented and sequenced using an Illumina HiSeq
platform at BGI (Beijing Genomics Institute). Reads were
mapped to the T. brucei 927 reference genome (v9.0, tritrypdb.
org) with Bowtie 2 (58) using the following parameter: very-
sensitive-local-phred33. The generated alignment files were
manipulatedwith SAMtools (59) and a custom script to identify
readswith barcodes (GCCTCGCGA) (57). Total and bar-coded
reads were then quantified using the Artemis genome browser
(60). Hit-lists generated from RIT-seq analyses excluded
selected large gene families, including variant surface glycopro-
teins, and genes immediately adjacent to hits.
T. brucei RNAi Constructs and Strains—PCR primers were
designed using RNAit (61) to generate a 536-bp fragment
conferring specific knockdown to FT1–3 (forward, GATCGGG-
CCCGGTACCGCTTGTGAGTTGGGTTTGGT, and reverse,
GATCTCTAGAGGATCCCGATCACAAGTGGAAGAGC).
PCR fragments were cloned in the pRPaSLi construct for the
generation of stem-loop dsRNA under the control of tetracy-
cline as the trigger for RNAi (56, 62). Constructs were digested
with AscI, ethanol-precipitated, and resuspended (1 g ml1)
in sterile water. 2T1 strains, containing a tetracycline repressor
(56), were electroporated using program X-001 of the Nucleo-
fector II electroporator (Amaxa, Cologne, Germany) (63) fol-
lowing the addition of 5 g of linearized DNA mixed in 100 l
of cytomix (64). Transformants were cloned by limiting dilu-
tion under phleomycin (1 g ml1) and hygromycin (2.5 g
ml1) selection. Puromycin susceptibility (1 g ml1) was
tested for full integration of the construct, and expression of
stem-loop RNAi was induced with 1 g ml1 tetracycline.
Quantitative RT-PCR—T. brucei RNA was isolated using an
RNeasy purification kit (Qiagen) and cDNA-synthesized using
a high capacity RNA-to-cDNA kit (Applied Biosystems). PCR
primers were designed using the Premierbiosoft’s Beacon
Designer 6 to amplify a 117-bp region common to all three FT
genes but distinct from the region targeted by RNAi (forward,
GAATTGCTGACAACATCATT, and reverse, TCACTGCG-
TAACCAAATGTA). qRT-PCRs consisted of 1 l (40 ng) of
cDNA, 10 l of Brilliant III Ultra-Fast QPCRMaster Mix (Agi-
lent Technologies), 1 l (500 nM) each of the forward and
reverse primers, and 0.3 l (30 nM) of reference dye and
nuclease-free PCR grade-treated water. PCR was performed
using an Agilent Mx3005P machine with the following cycling
conditions: 95 °C for 3 min; 40 cycles of 95 °C for 20 s; then
60 °C for 20 s. The reference gene TERT (Tb927.11.10190,
telomerase reverse transcriptase)was used to provide a baseline
of transcription levels for normalization of the data (forward,
AGGAACTGTCACGGAGTTTGC, and reverse, AGGAACT-
GTCACGGAGTTTGC). Relative quantification in the tetracy-
cline-induced FT1–3 knockdown cell line was normalized to
the un-induced cell line using the 

Ct method, and a
Student’s unpaired t test was used to show significance on four
experimental replicates. Statistical analyses were performed
using Excel and GraFit 5.013 (Erithacus software).
EC50 Determination of Antifolates—EC50 of antifolates in FT
knockdown lines were determined after 3 and 6 days of induc-
tion with tetracycline in TBM. Serial doubling dilutions of anti-
folates (5–50 mM stocks prepared in DMSO) were prepared in
96-well microtiter plates in 100 l of TBM, and trypanosomes
(resuspended in the samemedium)were added in 100l to give
a final density of 2.5 103 cellsml1 in 96-well plates. All wells,
including controls, contained a final volume of 0.5% DMSO.
Cultures were incubated for 72 h at 37 °C, 5% CO2 before cell
density was determined using a resazurin-based assay (65).
EC50 values were calculated usingGraFit version 5.0.13 (Eritha-
cus Software) with a 3-parameter fit from triplicate readings. A
weighted mean from three independent experiments was
calculated.
Transport Assay—T. brucei cells were grown in TBM for 72 h
at an initial seeding density of 5  103 cells ml1. Cells were
harvested by centrifugation (800 g, 10min, 4 °C), washed, and
resuspended in transport buffer (33 mM HEPES, 98 mM NaCl,
4.6 mM KCl, 0.55 mM CaCl2, 0.07 mM MgSO4, 5.8 mM
NaH2PO4, 0.3 mMMgCl2, 23 mMNaHCO3, 14 mM glucose, pH
7.3) (66) at a density of 2.5  108 cells ml1. Transport assays
were carried out as described previously by Ong et al. (67).
Uptake was initiated by mixing 100 l of cells with 100 l of
transport buffer containing 0.5 Ci of radiolabeled ligand (and
potential inhibitors of transport, where indicated) and layered
over 100 l of dibutyl phthalate (Sigma) in a 1.5-ml microcen-
trifuge tube. Transport was stopped by centrifugation of cells
through the dibutyl phthalate layer (16,000  g for 1 min).
Microcentrifuge tubes were flash-frozen in liquid nitrogen, and
the bottom of the tubes containing the cell pellets were cut off
directly into scintillation vials. Pellets were solubilized in 1 M
NaOH (150 l) overnight and mixed with scintillation fluid (2
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ml), and radioactivity was measured using a liquid scintillation
counter (Beckman Coulter).
Transport Kinetics—Uptake of [3H]folic acid (0.04 M) was
determined in the presence of varying concentrations of unla-
beled folate. Similarly, uptake of [3H]MTX (0.07M)was deter-
mined in the presence of varying concentrations of unlabeled
MTX. Uptake of both folate and MTX was determined at reg-
ular time intervals (30, 60, 90, 120, and 150 s) at 23 °C and fitted
using robust non-linear fitting to the linear equation ymx
c. The nonspecific binding of radiolabeled ligand to trypano-
somes at 4 °C was determined in a similar fashion. To calculate
Km, results were fitted by non-linear regression to the Michae-
lis-Menten equation.Aweightedmean from three independent
experiments was calculated.
Folate and MTX Inhibition Studies—Linear rates of uptake
were measured as before in the presence of 100 M competing
inhibitor with the standard assay mixture modified to contain
folate (2.0 M) or MTX (13 M) at approximately [S]  Km.
Inhibitor concentrations giving 50% inhibition (IC50) were then
determined over a range of concentrations across 7–8-point
serial doubling dilutions. Dose-response curves were fitted by
non-linear regression to a two-parameter IC50 equation using
GraFit 5.0 (Erithacus software). To determine themode of inhi-
bition of MTX on folate uptake and folate onMTX uptake, the
linear rate of uptake was measured as before using four differ-
ent substrate concentrations and three different inhibitor con-
centrations. The resulting data were plotted as a Lineweaver-
Burk transformation, and the graphs were inspected to
establish the most likely mode of inhibition (intersection on y
axis). An F test confirmed themode of inhibition as competitive
rather thanmixed. The entire data setwas then globally fitted to
the competitive Equation 1.
v 
VmaxS	
Km1 1	Ki  S	
(Eq. 1)
If folate and methotrexate are competitive substrates for the
same transporter, then, for folate we obtain Equation 2,
vF
Vmax
F F	
Km
F1 M	KmM  F	

Vmax
F /Km
F F	
1
M	
Km
M 
F	
Km
F
(Eq. 2)
and for methotrexate we get Equation 3,
vM
Vmax
M M	
Km
M1 F	KmF  M	

Vmax
M /Km
MM	
1
F	
Km
F 
M	
Km
M
(Eq. 3)
where [M] and [F] refer to the concentrations of methotrexate
and folate, respectively. Dividing Equation 3 by Equation 2
yields Equation 4,
vMvF Vmax
M /Km
MM	
Vmax
F /Km
FF	  (Eq. 4)
The IC50 for methotrexate ([M] IC50M) is defined in Equa-
tion 5 when
vMvF 0.5 (Eq. 5)
Substituting Equation 5 into Equation 4 and rearranging
yields Equation 6
IC50
M 
0.5Vmax
F /Km
F F	
Vmax
M /Km
M
(Eq. 6)
Likewise, the IC50 for folate, defined in Equation 7, can be
obtained from Equation 4 when vF/vM 0.5,
IC50
F 
0.5Vmax
M /Km
MM	
Vmax
F /Km
F 
(Eq. 7)
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